StartSUNPHARMA • NSE
add
Sun Pharmaceutical Industries Ltd
Seneste lukkekurs
1.683,10 ₹
Dagsinterval
1.669,00 ₹ - 1.689,00 ₹
Årsinterval
1.455,05 ₹ - 1.960,35 ₹
Markedsværdi
4,03 bio. INR
Gns. volumen
2,84 mio.
P/E-værdi
35,63
Udbytteprocent
0,95 %
Primær børs
NSE
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(INR) | mar. 2025info | År til år-ændring |
---|---|---|
Indtægt | 129,59 mia. | 8,14 % |
Driftsudgifter | 75,61 mia. | 20,16 % |
Nettoindtægt | 21,50 mia. | -19,01 % |
Overskudsgrad | 16,59 | -25,10 % |
Earnings per share | 10,01 | -13,02 % |
EBITDA | 34,05 mia. | 9,13 % |
Effektiv afgiftssats | 33,68 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(INR) | mar. 2025info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 249,88 mia. | 30,89 % |
Samlede aktiver | 921,01 mia. | 7,77 % |
Samlede passiver | 196,15 mia. | 6,85 % |
Samlet egenkapital | 724,86 mia. | — |
Shares outstanding | 2,39 mia. | — |
Kurs/indre værdi | 5,57 | — |
Afkast af aktiver | — | — |
Afkast af kapital | 9,40 % | — |
Pengestrøm
Nettoændring i likviditet
(INR) | mar. 2025info | År til år-ændring |
---|---|---|
Nettoindtægt | 21,50 mia. | -19,01 % |
Pengestrøm fra drift | — | — |
Pengestrøm fra investering | — | — |
Pengestrøm fra finansiering | — | — |
Nettoændring i likviditet | — | — |
Fri pengestrøm | — | — |
Om
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Grundlagt
1983
Hovedkvarter
Website
Ansatte
43.000